Investorideas.com

Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


investorideas.com - A Leading Global Investor Website for Biotech Industry Stocks

Investing in biotechnology stocks, pharma, medical technology and telemedicine has never been more exciting for investors with all of the new breakthroughs in technology and health. Let Investor Ideas help you find your next big idea in the sector with our free stock directories and news alerts. Don't miss out on the chance to invest in the future of healthcare and technology!

Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech Stocks

Investorideas Featured Company: Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Get news alerts on this company!

Biotech News

Oncology Stock News Bite - G1 Therapeutics (NASDAQ: GTHX) Trades Up on Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Oncology Stock News Bites - G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2023.

Biopharma Stock News Bite - Janux Therapeutics, Inc. (Nasdaq: JANX) Spikes over 200% on News Making it Nasdaq's Top Gainer
February 27, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biopharma Stock News Bites - Janux Therapeutics, Inc. (Nasdaq: JANX) a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced positive updated clinical data for both of its clinical programs.

Biotech Stock News Bite - Krystal Biotech (NASDAQ: KRYS) Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
February 26, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Krystal Biotech, Inc. (NASDAQ: KRYS), a commercial-stage biotechnology company reported financial results and key business updates for the fourth quarter and year ending December 31, 2023.

Biotech Stock News Bite - Immunic, Inc. (Nasdaq: IMUX) Year End 2023 Financial Results and Provides Corporate Update
February 22, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Biotech Stock News Bite - Ventyx Biosciences, Inc. (NASDAQ: VTYX) Makes Top Gainer List on NASDAQ
February 21, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Biotech Stock News Bites- Ventyx Biosciences, Inc. (NASDAQ: VTYX) makes the NASDAQ list of one of the top percentage gainers as the stock trades at $5.12, up $2.13 (+71.38%) on over 76 million shares.

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
SAN DIEGO - February 21, 2024 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for Santersus' NucleoCapture and HemoNucleoCapture devices.

Focus on Biotech and AI Stocks: (Nasdaq: IMTX) (Nasdaq: MDAI) (NASDAQ: BFRG) (CSE: INVR)
February 21, 2024 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, AI, Tech and Cybersecurity sectors.

Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData
February 20, 2024 (Investorideas.com Newswire) The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalization shifts in 2023 amid the macroeconomic headwinds

Focus on Biotech Stocks: (NASDAQ: CRDL) (NASDAQ: KA) (TSXV: MDCX) (OTCQB: SKYE)
February 16, 2024 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech sector.

Life Sciences Stock News Bite - Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
February 15, 2024 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com) Life Sciences Stock News Bites- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) , a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the United States Food and Drug Administration has granted Orphan Drug Designation for the Company's lead small molecule drug candidate for the treatment of pericarditis

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Biotech News from Newsfile

Cell MedX Corp. Announces Resignation of Director
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - Cell MedX Corp. (OTC Pink: CMXC) ("Cell MedX", or the "Company") a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote anti-aging and general wellness, announces the resignation of Brad Hargreaves from the Board of Directors of the Company. The resignation of Mr. Hargreaves was not due to any disagreement with the Company on any matter relating to...

PlantFuel Advances Its Innovative Product Portfolio with Amplify Nutrition Pre-Workout and Electrolyte Gummies
Toronto, Ontario--(Newsfile Corp. - February 28, 2024) - PlantFuel Life Inc. (CSE: FUEL) (OTCQB: PLFLF) (FSE: BR1B) ("PlantFuel" or the "Company") — PlantFuel, a pioneering force in the plant-based nutrition industry, is thrilled to announce significant progress with its latest product offerings, Amplify Nutrition Pre-workout and Electrolyte Gummies. PlantFuel has successfully engaged manufacturing partners to produce initial production of its proprietary recipes, setting the stage for future...

BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities
Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic partnership to develop better diagnostic tools to enhance lung cancer screening and improve breast cancer screening...

ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of Immuno-Oncology, is pleased to announce a non-brokered private placement financing to raise gross proceeds of up to $1,550,000 (the "Offering") and to provide an update on the status of its current research and development programs.The Offering...

PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
Toronto, Ontario--(Newsfile Corp. - February 27, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce that current board member Dr. David Kideckel has been appointed Chairman of the Board of PharmaDrug replacing Robert Steen who will remain as CEO of...

Subscribe to Biotech News